Project: The development of a novel nasal therapy containing antimicrobial peptides to treat MRSA carriage
The aim of this project is to develop a nasal therapy with antimicrobial peptides (AMPs) to eradicate Methicillin-resistant Staphylococcus Aureus (MRSA) carriage. The synthetic AMPs that were previously developed by Madam Therapeutics and LUMC have shown to be fully effective against antibiotic-resistant bacterial strains in in vitro models, including MRSA. At the end of this project, an AMP-based nasal cream will be available, with associated Proof-of-Mechanism and safety data package.
| Acronym | NASAMP (Reference Number: 9071) |
| Duration | 01/09/2014 - 01/09/2017 |
| Project Topic | Biological Sciences / Technologies |
| Network | Eurostars 2 |
| Call | Eurostars Cut-Off 1 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 19390 | Leiden Universitair Medisch Centrum | Partner | Netherlands |
| 19391 | Madam Therapeutics B.V. | Coordinator | Netherlands |
| 19392 | Aurigon Life Science GmbH | Partner | Germany |
| 19393 | MedPharm Ltd | Partner | United Kingdom |